| |
 |
|
|
|
|
|
Poster: 11
Visits: 203
Title: FIL-VERAL12: phase II randomized study with Rituximab-DHAP /- Bortezomib as induction in young relapsed/refractory Diffuse Large B-cell Lymphoma eligible to transplant.
Authors: ANNALISA CHIAPPELLA , Balzarotti M, Cabras MG, Merli F, Pogliani EM, Zaja F, Ciccone G, Martelli M, Pileri S and Vitolo U
Centre: On behalf of Fondazione Italiana Linfomi
|
|
You must be registered to reply or comment.
|
|
FIL-VERAL12: PHASE II RANDOMIZED STUDY WITH RITUXIMAB-DHAP /- BORTEZOMIB AS INDUCTION IN YOUNG RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE TO TRANSPLANT.
|
|
| You must be registered to reply or comment. |
|
|
|
|
|
|
| Most viewed poster for this congress |
|
|
Poster: 9
Visits: 649
Title: Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial
Authors: Michael Wang ,
Centre: The University of Texas MD Anderson Cancer Center
|
|
|
|
|
|
|
| Poster most viewed in this topic |
|
|
Poster: 14
Visits: 271
Title: CLLR3 A randomized Phase II trial evaluating the chemotherapies FC/ B combined with GA101 followed by GA101 maintenance in relapsed/ refractory CLL
Authors: Nadine Kutsch ,
Centre: University Hospital of Cologne
|
|
|
|
